Human IFIH1 blocking peptide

Product Overview

Blocking/Immunizing peptide for anti-MDA5/IFIH1 antibody

Target

MDA5 / IFIH1

Nature

Synthetic

Tag/Conjugate

Unconjugated

Application Notes

For in vitro research use only. Not intended for any diagnostic or therapeutic purpose. Not for human or animal consumption.

Format

Lyophilized powder

Preservative

None

Storage

Shipped at ambient temperature, store at -20°C.

Entrez Gene ID

Antigen Description

DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. Based on their distribution patterns, some members of this family are believed to be involved in embryogenesis, spermatogenesis, and cellular growth and division. This gene encodes a DEAD box protein that is upregulated in response to treatment with beta-interferon and a protein kinase C-activating compound, mezerein. Irreversible reprogramming of melanomas can be achieved by treatment with both these agents; treatment with either agent alone only achieves reversible differentiation. Genetic variation in this gene is associated with diabetes mellitus insulin-dependent type 19. [provided by RefSeq, Jul 2012]

Function

ATP binding; DNA binding; double-stranded RNA binding; double-stranded RNA binding; helicase activity; protein binding; ribonucleoprotein complex binding; single-stranded RNA binding; zinc ion binding;

Synonyms

IFIH1; interferon induced with helicase C domain 1; Hlcd; MDA5; MDA-5; RLR-2; IDDM19; interferon-induced helicase C domain-containing protein 1; helicard; CADM-140 autoantigen; RIG-I-like receptor 2; helicase with 2 CARD domains; RNA helicase-DEAD box protein 116; murabutide down-regulated protein; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide; melanoma differentiation associated protein-5; melanoma differentiation-associated protein 5; clinically amyopathic dermatomyositis autoantigen 140 kDa;